Objective: The aims were to validate the use of a direct reading NO electrode, to compare the effects of diverse acting drugs on Ž . altering coronary flow CF and NO release, and to examine the effects of altered perfusion pressure on flow-induced changes in NO w x concentration NO in the hemoglobin free effluent of guinea pig isolated hearts. Methods: Hearts were isolated and perfused initially at a Ž . constant perfusion pressure 55 mmHg with a modified Krebs-Ringer's solution equilibrated with 97% O and 3% CO at 378C. Heart 2 2 rate, left ventricular pressure, CF, and effluent pH, pCO , pO , and NO generated current were monitored continuously on-line. Effluent 2 2 w x was sampled for L-citrulline. Percent O extraction and O consumption were calculated. NO was quantitated with a sensitive 2 2 Ž . amperometric sensor sensitivity G 1 nmolrlf 3 pA and a selective gas permeable membrane. Results: The electrode was not sensitive Ž . Ž to changes in solution pO , flow, or pressure. The electrode was sensitive to pCO y0.50 nmolrlrmmHg and temperature q24.5 2 2 . nmolrlr8C , so coronary effluent pCO was measured to compensate for a small decrease in pCO that occurred with an increase in 2 2 coronary flow, and effluent temperature was rigidly controlled. Serotonin, bradykinin, and nitroprusside increased NO release along with w x CF, whereas nifedipine, butanedione monoxime, zaprinast, and bimakalim comparably increased CF but did not increase NO or NO Ž . Ž . release. Increases in CF mlrgrmin and NO release pmolrgrmin , respectively, were 5.0 " 1 and 100 " 17 for 1 mmolrl serotonin, 7.5 " 1 and 148 " 18 for 100 nmolrl bradykinin, and 7.8 " 1 and 173 " 28 for 100 mmolrl nitroprusside. The increases in effluent NO by bradykinin were proportional to the increases in L-citrulline. Tetraethylammonium decreased CF, but did not change NO release, G Ž . indomethacin changed neither CF nor NO release, and N -nitro-L-arginine methyl ester L-NAME reduced CF by 2.6 " 1 mlrgrmin and NO release by 25 " 8 pmolrgrmin. An increase of CF of 8.0 " 0.3 mlrgrmin, produced by increasing perfusion pressure from 25 w x to 90 mmHg, increased NO by 30 " 4 nmolrl; L-NAME but did not reduce the pressure-induced increase in CF, but reduced the w x increase in NO to 10 " 5 nmolrl. Conclusions: This study demonstrates in intact hearts real-time release of NO by several vasodilator Ž . drugs and by pressure-induced increases in flow shear stress and attenuation of these effects by L-NAME. q
Introduction w x
Endothelium-derived relaxing factor 1 is most likely Ž . w x nitric oxide NO 2-4 . NO is normally generated in the circulation via stimulation of vascular endothelial NO synTime for primary review 23 days.
0008-6363r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved. . thase eNOS by endothelial mechanochemical receptors w x 4,5 . NO can also be released from nitrosyl compounds Ž . w x such as nitroprusside NP at guanylyl cyclase 6,7 . NO gas released abluminally stimulates vascular smooth muscle guanylyl cyclase to elicit vasodilation by increasing w x cGMP 4 . Many vasodilator drugs are thought to act predominately through either endothelium-dependent or -independent pathways.
It has been demonstrated directly and indirectly that NO is released from coronary endothelium and that it moduw x lates coronary vascular tone, at least in vitro 8-11 . However, there has been no direct information on whether a given vasodilator stimulates NO production, how pres-Ž . sure-induced changes in coronary flow CF affect NO production, if NO contributes fo flow reulation, and how drug and mechanically induced NO production is affected by eNOS antagonism in the intact coronary vascular bed. Several methods have been reported that indirectly meaw x sure NO 10-16 . More recently, highly specific amperometric sensors for NO have been developed for real-time w x measurement of NO from cells or intact tissues 17-21 . To elucidate the role of NO on local control of the intact coronary circulation we quantitated, in real time, coronary effluent release of NO from intact hearts during increases in CF induced by endothelium-dependent and -independent drugs, measured NO release resulting from Ž . pressure-induced changes in CF shear stress , and assessed effects of an eNOS antagonist and other antagonists on altering CF and NO responses. Advantages to the use of the crystolloid perfused, isolated heart were that effluent NO release could be monitored continuously on-line with CF and effluent pO in the absence of hemoglobin which 2 w x inactivates luminally released NO, that effluent NO could be measured during either drug or flow-induced endothew x lial stimulation, and that effects of inhibitors on NO and NO release could be assessed.
After extensive testing for artifacts, and after demonstrating the effectiveness of the electrode to measure NO when placed in the coronary effluent, our specific objec-Ž . tives were: 1 to measure and compare the effects of eight Ž . known vasodilators to release NO and increase CF; 2 to measure release of NO when CF was altered by step Ž . changes in coronary perfusion pressure; 3 to confirm drug-induced NO release by measuring release of L-citrul-Ž .
G line, its co-product; and 4 to compare effects of N -Ž . nitro-L-arginine methyl ester L-NAME , a NOS inhibitor, Ž . indomethacin INDO , a prostaglandin synthesis inhibitor, Ž .
q and tetraethylammonium TEA , a non-specific K channel blocker, on CF and NO production. The drugs selected Ž . Ž . were: serotonin 5-HT and bradykinin BK , eNOS-de-Ž . pendent dilators; nitroprusside NP , a NO releaser at Ž . . effects in both cell types. INDO, indomethacin; PGI , prostaglandin I ; BDM, butanedione monoxime; 5-HT, 5-hydroxytryptamine serotonin ; BK, 2 2 bradykinin; NP, nitroprusside; L-NAME, nitro L-arginine methylester; NIF, nifedipine; ZAP, zaprinast; TEA, tetraethylammonium; BIM, bimakalim. PL, phospholipids; PLA , phospholipase A ; AA, arachidonic acid; COG, cyclooxygenase, PGS, prostaglandin synthase; L-arg, L-arginine; NOS, nitric oxide 2 2 Ž . synthase; NO, nitric oxide; G, G guanine nucleotide-binding protein; cAMP, cyclic adenosine monophosphate; AC, adenylyl cyclase; cGMP, cyclic guanine monophosphate, SGC, soluble guanylyl cyclase; PDE IV, phosphodiesterase type IV. 
Methods

Langendorff heart preparation
The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US Ž National Institutes of Health NIH publication No. 85-23, . revised 1995 . After approval was obtained from the institutional Animal Studies Committee at the Medical College of Wisconsin, 10 mg of ketamine and 1000 U of heparin were injected intraperitoneally into 45 albino English Ž . short-haired guinea pigs 250-300 g . The description of the surgical preparation for this model has been reported in w x detail previously 22 . The animals were decapitated when unresponsive to noxious stimulation. After thoracotomy, the inferior and superior venae cavae were ligated and cut and the aorta was cannulated distal to the aortic valve. Each heart was perfused in retrograde fashion through the aorta with cold, oxygenated, modified Krebs-Ringer's solution equilibrated with 97% O and 3% CO and was 2 2 then rapidly excised. temperatures were maintained tightly at 37.2 " 0.18C using a thermostatically controlled water circulator to jacketed glass tubing, bath, and aluminum heat exchangers.
Ž . Left ventricular pressure LVP was measured isovolumetrically with a transducer connected to a thin, saline-Ž filled latex balloon Hugo Sachs Electronic KG, March-. Hugstetten, Germany inserted into the left ventricle through the mitral valve from a cut in the left atrium. Balloon volume was adjusted to maintain a diastolic LVP of zero mmHg during the initial control period. Two pairs Ž of bipolar electrodes Teflon-coated silver, diameter 125 . mm, Cooner Wire Chatsworth, CA were placed in each heart to monitor intracardiac electrograms from which Ž . spontaneous atrial heart rate HR was determined from the right atrial beat-to-beat interval.
Ž . Ž . Coronary aortic inflow CF was measured at constant temperature and at a nominal aortic perfusion pressure of 55 mmHg by a self-calibrating in-line ultrasonic flow Ž meter Transonic T106X small animal blood flow meter;
. Transonic System, Ithaca NY placed directly into the aortic inflow line. Basal flow for all studies was 6.3 " 2 Ž mlrgrmin. Maximal CF was elicited with adenosine 0.2 . ml of 200 mmolrl stock solution injected directly into the aortic root cannula during the initial control period and after the last control reading. Beginning and ending flow Ž . responses to adenosine arrested hearts were 16.3 " 2 and 12.5 " 3 mlrgrmin, respectively, for all groups combined. In six hearts perfusion pressure was changed abruptly from 55 to 25, from 25 to 55, from 55 to 90, and from 90 to 55 mmHg for 5 min at each level to simultanew x ously measure steady-state changes in flow and NO .
Nitric oxide, oxygen and pH measurements
Coronary sinus effluent was collected by placing a small, gas impermeable cannula into the right ventricle through the pulmonary artery after ligating the superior assumed constant at 15 mmolrl; calculated effluent CO 2 tension at a given pH was verified off-line with the gas analyzer.
NO concentration was measured as the change in redox Ž . current pA generated by a gas permeable, water imper-Ž meable NO electrode ISO-NOP 2 mm, World Precision . Instruments, Sarasota, FL . The electrode probe measures NO concentration in aqueous solutions polarographically w x 20 . The electric current is generated as NO diffuses through the membrane and becomes oxidized at the platinum electrode. The generated current is proportional to diffusion of NO through the membrane and diffusion is based on its partial pressure which, in turn, is proportional w x to NO at the probe tip. Current is measured with a sensitive amperometer during zero voltage suppression to expand the response range. Selectivity of the membrane for NO over other gases is determined by the potential Ž applied to the electrode. The presence of NO gas 2NO q 2 . O s 2 NO could generate a current but in aqueous 2 2 solution NO is highly unstable and at physiological pH 2 degrades to NO y and NO y which do not penetrate the 2 3 membrane. A possible effect CO on altering pH of the 2 internal electrolyte solution was minimized by used a Ž . two-part buffered electrolyte solution catalog no. 7521 furnished by the supplier.
NO calibration curves were generated by graded chemical production of NO at 378C in a stirred bath where KI and H SO are in excess: 2NaNO q 2KI q 2H SO s 2 . Significant effect of temperature on apparent NO current. For a w x 18C increase in electrode temperature apparent NO increased by 24.5 nmolrl. ns12 studies conducted in the Langendorff apparatus in the absence of hearts. The effect of increased coronary effluent flow to increase effluent temperature was circumvented by enclosing the NO electrode and flow through tubing in a water jacketed aluminum block so that temperature was maintained constant.
Ž .
Ž . carried out 1 day after changing the gas permeable membrane and internal filling solution which were changed Ž . weekly. Five point calibration curves n s 14 of current Ž . w x Ž . pA as a function of NO 50-1000 nmolrl gave a Ž 2 . Ž . correlation coefficient r of 0.99 P -0.001 , a slope of Ž . 2.92 " 0.16 95% confidence intervals and a y-intercept Ž . of 9.4 " 41 pA P ) 0.1 . For every pA increase in current, NO concentration therefore increased by 0.34 nmolrl. There was no significant change in NO electrode sensitiv-Ž . ity G 1 nmolrl over a 1-week period. Transient time Ž . from the right ventricle coronary sinus cannula to the NO electrode determined by methylene blue infusion, was 0.5 s at a flow of 5 mlrmin.
Percentage O extraction was calculated as the differ-2 ence between inflow and outflow tensions multiplied by 100, and divided by inflow O tension. Percent O extrac- 2 2 tion was measured in all studies and used to assess direct vasodilatory responses separate from those due to an autoregulatory response, e.g. a decrease in CF secondary to decreased contractility. In the absence of O debt, an Ž . and NO electrode current pA were displayed continu-Ž . ously on a fast-writing 3 kHz , high resolution, eight Ž . channel chart recorder Astro-Med, West Warwick, RI .
Ž . Ž . NO pA and pH mV electrode signals were zero suppressed and amplified for continuous display.
Measurement of L-citrulline
L-Citrulline was measured in coronary effluent samples of eight hearts in the absence and presence of 0, 0.1, 1, and duced equivalent increases in coronary flow, but no significant increases w x in NO . NOSrGC, nitric oxide synthaserguanylyl cyclase. . cm was perfused at a mobile phase flow rate of 1.5 mlrmin. The detector potential was set at q0.7 V. The mobile phase consisted of 800 ml 0.1 molrl sodium acetate, pH adjusted to 5.7, plus 260 ml acetonitrile. L-Citrulline was detected electrochemically as the o-Ž . phthaldialdehyde OPA derivative. The OPA reagent con-Ž . sisted of 25 ml 0.1 molrl borate buffer pH 9.5 , 50 ml of 2-methyl 2-propanethiol, 2.5 ml methanol, and 135 mg of o-phthaldialdehyde. All chemicals were HPLC grade. Chromatographic data was collected on a Hewlett Packard 3393A integrator and stored on a Hewlett Packard 9122 Ž . disc drive. Coronary venous effluent was collected 2 ml during drug-free control periods and during the last 30 s of BK infusion and frozen at y158C. Samples were later prepared and analyzed as follows: to each 0.5 ml sample Ž . was added 25 ml of methyl-L-arginine 2 mgrml as an internal standard. Three ml ethanol was added to each sample, mixed, and centrifuged. The supernatant was transferred to a clean tube and evaporated to dryness under a stream of air at 408C. The dried residue was redissolved in 2.0 ml of mobile phase and 400 ml was mixed with 40 ml of the OPA reagent for exactly 2.00 min prior to injection of 100 ml into the HPLC. L-Citrulline concentration was calculated from the standard curve of the respective peak height ratio versus concentration. Standard curve data were derived using perfusate that did not pass through the isolated heart. L-Citrulline standard curves was linear over the concentration range studied. The limit of detectability was 1 ngrml perfusate. The absolute retention time for L-citrulline was 10.3 min.
Protocol
Experiments to validate the NO electrode were conducted in the experimental setup, in the absence of hearts, using a flow restrictor between the inflow and outflow tubing to imitate the coronary circulation. Factors examined for their potential artifactual effects on the NO elec-Ž . trode were flow, pressure, O and CO tensions pH , and 2 2 temperature. Preliminary trials were then undertaken in 14 isolated hearts to tightly control heart and effluent temperature and to measure effluent pH with changes in flow Ž . data not reported . After preliminary trials were completed, eight differently acting vasodilator drugs were examined for effects on CF, on other cardiac variables, and on release of NO, in 14 additional hearts. Adenosine was given to determine maximal flow, and at least 30 min was allowed to stabilize variables before obtaining initial control measurements.
Dose response curves were generated for randomly Ž . 
in each heart to minimize any drug interactions or long term effects. CF and NO current returned approximately to the control level after washout of each drug. The putative site of action of several of these drugs on vasodilator pathways is shown in the simplified schema Ž . Fig. 1 .
The role of several inhibitors of endogenous vasodilators on basal CF and release of NO was examined in 11 additional hearts. The individual and combined effects of Ž . Ž single concentrations of INDO 20 mmolrl , TEA, 10 . Ž . mmolrl , and L-NAME 100 mmolrl were assessed for their effects on lowering basal CF and altering NO. Basal Ž . absolute NO concentration was not measured, but was Ž . inferred after NOS inhibition by L-NAME see Section 3 . Effect of these inhibitors to blunt vasodilation induced by Ž . BK 1, 10, 100 mmolrl was also examined. In 6 addi- 
Ž . and absence of L-NAME 100 mmolrl .
Measurements were obtained during the peak steady state change in CF during exposure to each concentration of a drug infused for 5 min. All drugs and concentrations were given in random fashion. Drug vehicles had no effects on any variable measured. There was a 10 min drug-free washout period between each drug administra-Ž . Ž . tion. NO concentration nmolrl or release pmolrgrmin were expressed as the change from the preceding control. After the last control period, adenosine was again injected at the same concentration into the aortic cannula to observe any change in maximal CF reserve.
Statistics
All data are expressed as means " s.e.m. or slope " 95% confidence intervals. Individual drug responses were compared to the preceding control by paired Student's t-tests.
Ž . Dose-response curves to bradykinin BK were compared by Tukey's comparison of means tests following ANOVA Ž for repeated measures Super Anova 1.11 software for . Macintosh from Abacus Concepts, Berkeley, CA . Calibration curves for NO and NO electrode responses to flow, Ž pressure, oxygen, temperature and CO in the absence of 2 . hearts , and the CF to NO release relationship in the presence of several concentrations of vasodilatory drugs, were fitted by linear regression analysis to determine correlation coefficients, significance of slopes and confidence intervals. Equations are of the form Y s mX q B, where Y is a function of X, and m s slope, and B s Y slope intercept. Differences among means were considered statistically significant when P F 0.05.
Results
Validation of nitric oxide electrode
Within the physiological range of studies conducted in the isolated hearts, but in the absence of hearts, the NO electrode was insensitive to changes in flow between 0 and Ž 2 . 30 mlrmin Y s 0.007 P flow q3.8; r s 0.15; P ) 0.1 , Ž O tension between 50 and 250 mmHg Y s 0.0001 P pO 2 2 Ž .
2
. mmHg q 1.26; r s 0.01; P ) 0.1 , and pressure above barometric between 10 and 100 mmHg at 10 mlrmin Ž 2 constant flow Y s 0.005 P mmHgq 2.1; r s 0.01; P ) . 0.1 . The NO electrode was markedly sensitive to artificially induced changes in bath temperature in the absence Ž . Ž . of hearts q24.5 nmolrlr8C Fig. 2 . To control for this effect during isolated heart experiments, the temperature of the coronary effluent passing through the NO electrode chamber was held to a change of -0.058C by the heat exchanger during a maximal range in flow of 4-18 mlrmin. Thus there was no appreciable change in coronary effluent temperature to alter NO electrode sensitivity. The NO electrode was slightly sensitive to changes in CO 2 induced by changing percent CO gas flow in the gas 2 mixing chamber in the absence of hearts. The small effect q Ž of a change in effluent H concentration y0.22 . Ž . nmolrlrmV , or pCO y0.50 nmolrlrmmHg , was 2 factored in at each data point by continuously measuring Ž . coronary effluent pH Fig. 3A,B . The maximal decrease Ž in coronary effluent CO tension from control CF 6.5 " 2 . 0.2 mlrgrmin to a maximal steady-state increase in CF Ž . 13.3 " 2 mlrgrmin was 4 mmHg, i.e., an apparent w x increase in NO of about 2 nmolrl. . w x L-NAME control , NO changed proportionally with coronary flow during changes in perfusion pressure. In the w x presence of L-NAME, basal coronary flow and basal NO decreased significantly at the control perfusion pressure of w x 55 mmHg. Fig. 10 illustrates that NO varied as a function of the change in pressure-induced steady-state change in Ž . w x CF without L-NAME control , but that NO did not vary as a function of a similar change in CF with L-NAME. w x When the change in NO was expressed as a linear function of change in CF over this pressure range, the Ž 2 . slope was 4.0 r s 0.87; P -0.01 without L-NAME and Ž 2 . 1.1 r s 0.31; P ) 0.1 with L-NAME. Overall, L-NAME Ž . Fig . 11A ,B shows individual and combined effects of inhibition of PG synthesis by INDO, non-specific K q channel blockade by TEA, and inhibition of NO production by L-NAME on decreasing basal CF and NO release. As shown, INDO had no effect on CF or NO release, TEA decreased CF by 18% without an effect on NO release, and L-NAME decreased CF by 24% and NO release by 25 pmolrgrmin. Together, these drugs reduced basal CF by up to 40% and NO release by up to 42 pmolrgrmin, but Ž . NO release was not different P ) 1.0 with all three drugs than with L-NAME alone. Fig. 12A ,B shows the effects of PG, NOS and nonspecific K q channel inhibition on BK-induced CF and w x effluent NO . INDO alone did not change CF; INDO q TEA decreased basal CF by 1.8 " 0.3 mlrgrmin but had w x no effect on basal NO . L-NAME alone or with INDO and TEA decreased basal CF by about 2.6 " 0.2 mlrgrmin w x from the drug free control and decreased basal NO by about 9.5 " 1.5 nmolrl. On stimulation by BK alone Ž . control , CF increased by up to 6.2 " 3 mlrgrmin by 10 w x nmolrl BK, and NO increased by up to 27 " 2 nmolrl in a concentration-dependent manner as similarly shown in Figs. 5 and 6 for NO release. INDO alone, or qTEA, had w x no significant effects on CF or NO responsiveness to BK, whereas L-NAME alone, or qINDOq TEA, abolished the increase in CF due to 0.1 nmolrl BK, and attenuated the increase in CF due to 1 nmolrl BK, whereas the increase w x in NO due to 0.1 and 1 nmolrl BK was abolished. Although L-NAME, alone or in combination with INDO or w x TEA, markedly attenuated the increase in NO induced by 10 nmolrl BK, CF was only slightly reduced from controls by L-NAME and by L-NAME q INDO in the presence of 10 nmolrl BK.
Effects of Õasodilators on coronary flow, NO release and cardiac function
Discussion
Validation of nitric oxide electrode
Our study demonstrates the capability for real-time detection and quantification of nitric oxide in hemoglobinfree coronary effluent of guinea pig isolated hearts by recording the change in current generated by a sensitive NO electrode placed within the pulmonary outflow Ž . coronary sinus effluent. We observed that the electrode was itself insensitive to flow, pressure, and O within the 2 physiologic ranges obtained in the isolated heart studies. However, because we found that the electrode is quite sensitive to a change in temperature and is moderately pCO sensitive, it was important to rigidly control coro-2 nary effluent temperature with a heat exchanger and to compensate for the small decrease in pCO that occurs 2 with an increase in CF. During extensive testing we found that NO electrode sensitivity to pCO is determined by 2 the buffering capacity of the internal filling solution. We were able to reduce CO sensitivity so that a maximal 2 physiological decrease in pCO of 4 mmHg increased the 2 apparent NO sensitivity less than 10%. However, we also found that a decrease in CO sensitivity is a trade off for a 2 shorter usable period before the membrane and filling solution must be changed and the system recalibrated. Consequently, the electrode membrane was changed and the electrode recalibrated once per week. Calibration curves were very reproducible from week to week.
Ex ÕiÕo measurement of nitric oxide
For the vast majority of studies on the role of NO on endothelial and vascular function investigators have used inhibitors of eNOS and measures of guanylyl cyclase activity or cGMP production as research tools. But there are now several methods to measure NO indirectly or w x directly in solutions. Bioassay 12 , chemiluminescence w x w x 2,9,13,14 , electron paramagnetic response spectra 15 , w x and spectrophotometric 8,16 methods have been used to quantitate NO levels. Compared to these assays, the NO sensitive electrode has several potential advantages in that it measures changes in NO-generated current continuously, i.e. in real time, in organ effluent or superfused tissues. There are a few reports in which NO electrodes have been w x used to measure NO in superfusate solution from brain w x and cultured vascular endothelial tissues 17,18,21 . In our experimental setup we were able to simultaneously measure coronary effluent NO, O and pH at constant tempera-2 ture. Changes in NO current were recorded within 0.5 s. The half-life of NO in aqueous solution lies between 3.8 and 5.6 s, but may be as short as 0.1 s when NO is perfused in an oxyhemoglobin solution through an isolated w x heart 8 . In our model, the tubing and electrode chamber were sealed against gas leakage. However, it remains possible that there is a proportionally small loss of NO after its release into hemoglobin-free Krebs-Ringer perfusate while in transit to the electrode, which would lead to w x an underestimated NO .
A direct measure of NO in isolated heart coronary effluent is useful to confirm the many indirect studies in which NO release has been implied by using inhibitors of eNOS such as L-NAME. More importantly, the NO electrode allows direct confirmation of which vasodilator drugs induce vasorelaxation via the eNOS-guanylyl cyclase pathway. There are several indirect reports, based on eNOS inhibition or perfusion of NO scavengers, that coronary flow in the guinea pig and dog is regulated by NO w x 8,23-25 . A potential limitation of our method is that vascular luminal release of NO may not reflect abluminal release of NO across interstitial fluid to the vascular smooth muscle cell. However, it is likely that NO luminal release is at least proportional to abluminal release in the coronary vascular bed perfused with a hemoglobin-free perfusate that imitates the interstitial fluid. The mean w x Ž . Ž decreases in NO 9.5 " 2 nmolrl and NO release 33 " 8 . pmolrgrmin, or 59 " 9 pmolrmin when L-NAME was Ž . infused suggests that these are basal unstimulated values w x w x for NO and NO release. Indeed, the decrease in NO by L-NAME was associated with a decrease in basal CF of about 20%. If this approximation is true, then stimulated endothelial production of NO, e.g. by 5-HT, increased w x absolute NO from about 10 nmolrl basally to about 30 Ž . nmolrl, a three-fold increase data of Figs. 7 and 12 . w x Kelm and Schrader 8 collected the coronary effluent of guinea pig hearts perfused with 4 mmolrl oxyhemoglobin and used a differential-spectrophotometric assay in which methemoglobin was produced in proportion to NO as NO combined with oxyhemoglobin. They estimated that basal release of NO was about 160 " 10 pmolrmin, more than w x twice that estimated in our study. Ellwood and Curtis 9 assessed NO production indirectly from frozen aliquots of coronary effluent from isolated guinea pig hearts by a chemiluminescence method. They reported a 5-to 10-fold greater increase in NO release with 5-HT and NP than we did using our real-time electrode measurement. It is unclear if our NO measurements are underestimated, or those of the other investigators are overestimated. Our companion studies of L-citrulline measurements show a three-fold Ž . larger concentration that that of NO Fig. 6 . 
Drug and pressure-induced changes in coronary flow and NO release
Our data shows that CF increases proportionately with . 225 pmolrmin at the heart weight average 1.6 g we obtained with 100 nmolrl BK. A major difference in our studies is that we did not perfuse hearts with the NO scavenger oxyhemoglobin so that NO effluent levels measured in our preparation more likely reflect interstitial Ž . abluminal production of NO. Moreover, we have measured the more stable metabolite of NOS, i.e. L-citrulline in coronary effluent and report that L-citrulline and NO concentration increase together with infusion of bradykinin Ž . Fig. 6 . Since L-Citrulline concentrations were about three times greater than the corresponding NO concentrations. This could result from endothelial re-uptake of NO, loss of NO on transit to the NO electrode, or NO degradation at guanylyl cyclase.
Along with our examination of effects of different exogenous vasodilators on stimulating release of NO and CF, we examined effects of changes in perfusion pressure Ž . Ž . w x wall stretch on coronary flow shear stress -induced NO as well as effects of endogenous vasodilatory factors that contribute to maintenance of basal coronary flow by blocking several pathways that lead to vasodilation. It has been reported that NO modulates coronary autoregulatory responses during changes in coronary perfusion pressure w x 8,23-25 . An increase in laminar flow over cultured enw x dothelial cells induces NO release 26 but NO release to w x continuous shear stress is transient 21 . Autoregulation, Ž . although incomplete between 25 and 90 mmHg Fig. 9B , was evidenced by a marked reduction in peak flow of about 50% induced by abrupt changes in perfusion pressure. Decreased and increased CF resulting from changes in perfusion pressure were associated with decreased and w x increased effluent NO , respectively, but in the presence of L-NAME the NO responses were significantly attenuated by approximately 67% while the pressure-induced w x flow responses were not. Our results indicate that NO indeed varies with pressure-induced changes in coronary Ž . w x flow shear stress and that L-NAME reduces basal NO and CF at normal perfusion pressure. However, our obserw x vation that L-NAME greatly attenuates changes in NO , but not changes in CF resulting from changes in perfusion pressure, suggests that factors in addition to NO contribute to autoregulation of CF. It is also possible that L-NAME does not completely block NO production and release.
It is noteworthy that pressure-induced changes in flow Ž . w x shear stress produced changes in NO , whereas the several eNOSrguanylyl cyclase-independent vasodilators, e.g. BIM or NIF, also similarly increased CF but did not w x Ž . Žw x . increase NO Fig. 7 . However, NO release NO P CF increased with several of these drugs with the increase in CF. It appears, therefore, that the NO vs. CF relationship in the intact heart is different if CF is increased by increasing perfusion pressure or by infusing vasodilatory drugs. Vasodilator drugs that are either eNOSrguanylyl cyclase-independent or -dependent increase CF by reducing smooth muscle tone so that vessel diameter is actiÕely increased and this may have no effect on shear stress despite the flow increase. On the other hand, pressure-induced changes in flow directly alter vessel diameter passiÕely by a change in the pressure gradient and so may produce a proportionate change in shear stress. This may explain why a large increase in CF by BIM is not accomw x panied by an increase in NO , whereas a comparable increase in CF -induced by an increase in perfusion w x pressure -is accompanied by an increase in NO . The rapidly attenuated initial peak CF response to an abrupt change in pressure could be due to myogenically mediated vasoconstriction.
There may be other complex reasons for these apparent w x differences in cause and effect between CF and NO w x 11,27 . Feedback mechanisms are probably quite different 28 . In our model it is not possible to separate pressure Ž . Ž . wall stretch from flow shear stress alterations as contributors to NO production. It is likely that drug-induced vasodilation overrides the metabolic autoregulatory mechanisms that maintain basal CF and lead to decreased O 2 extraction as we have observed, whereas pressure-induced vasodilation is counteracted by myogenic autoregulatory mechanisms so that CF is relatively maintained while causing coronary distension, increased transmural pressure, w x and decreased O extraction 29,30 . 2 Coronary vascular tone is modulated by many endogenous substances and one vasodilatory mechanism is clearly eNOS dependent. Other vasodilatory mechanisms can be unmasked with inhibitors. We found that non-specific q Ž . blockade of K channels TEA and blockade of NO Ž . production L-NAME reduced basal CF, but that only w x L-NAME reduced NO and NO release. Together, indo-Ž . methacin to block PG synthase inhibition , TEA and L-NAME reduced basal flow maximally by 40%, indicating a significant portion of basal vasodilation can be accounted for by blocking specific vasodilator pathways. If abluminal levels of NO reflect interstitial levels at the guanylyl cyclase receptor site for NO in smooth muscle, the data suggests that NO contributes to about 20% of basal CF.
Bradykinin has been reported to produce vasodilation w x by several mechanisms 31-34 . There may be a direct vasodilator effect on vascular smooth muscle at high BK concentrations. We additionally tested the vasodilatory effect of BK on CF and NO in the presence of indomethacin, andror TEA andror L-NAME. In our experiments, indomethacin alone did not alter the BK-induced increase in CF or release of NO. However, the combination of indomethacin and L-NAME and that of indomethacin, L-NAME and TEA, depressed the F 1 nmolrl BK-induced increase in CF and NO. Although 100 mmolrl of L-NAME completely blocked the release of NO to 10 nmolrl BK, it did not completely block the increase in CF. Thus in the presence of all three inhibitors of vasodilation, the BK-induced increase in CF could not be completely abolished. These results suggest that the major mechanism of vasodilation by BK below 1 nmolrl is dependent on Ž . NO release but at higher concentrations 10 nmolrl , BK exerts an additional mechanism of vasodilation, perhaps a direct effect on vascular smooth muscle.
In summary, these results demonstrate real-time release of NO directly into the vascular lumen of hemoglobin-free coronary effluent by endothelium-dependent drugs, sero-Ž . tonin 5-HT and bradykinin, as well as by nitroprusside. The release of NO is proportional to the increase in coronary flow by the eNOS dependent drugs and by nitroprusside. Inhibition of endogenous vasodilation due to w x eNOS activity by L-NAME is evidenced by reduced NO and NO release along with a decrease in CF. Drugs thought not to produce vasodilation via an eNOS-dependent mechanism, i.e., butanedione monoxime, zaprinast, bimakalim, PGE and nifedipine, indeed do not increase 1 w x NO . Pressure-induced changes in CF lead to proportional changes in effluent NO concentrations and these changes in NO, but not CF, are attenuated by eNOS antagonism. 
